Stocks and Investing Stocks and Investing
Tue, December 10, 2024
[ Tue, Dec 10th 2024 ] - Seeking Alpha
Payoneer Global: The Young Company Is A Strong Candidate For A Growth Portfolio
[ Tue, Dec 10th 2024 ] - The Motley Fool UK
3 ways to harness the wisdom of Warren Buffett when stock picking
[ Tue, Dec 10th 2024 ] - Seeking Alpha
SoundHound AI: Redefining Business With AI Customer Service Becoming A Critical Utility
[ Tue, Dec 10th 2024 ] - MSN
Prediction: Palantir Stock Will Soar After Dec. 13 (There's a Catch Though)
[ Tue, Dec 10th 2024 ] - Seeking Alpha
Telenor: Superb Income Is Very Likely To Continue
[ Tue, Dec 10th 2024 ] - The Motley Fool
Is It Smart to Buy Stocks With the S&P 500 at an All-Time High? History Has a Clear Answer.
[ Tue, Dec 10th 2024 ] - esquiremag
Financial Adviser: 5 Low-Priced Value Stocks in 2 .. 's 'Net-Net' Strategy and How to Profit from Them
[ Tue, Dec 10th 2024 ] - The Motley Fool
Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 2 Ultra-High-Yield Stocks.
[ Tue, Dec 10th 2024 ] - Seeking Alpha
VICI Properties: Why I Am Selling This Dividend Darling
[ Tue, Dec 10th 2024 ] - Seeking Alpha
Why Is Singapore Equity Attractive To Investors?
[ Tue, Dec 10th 2024 ] - AOL
Can You Invest in BlueSky Stock and Is It Worth It?
[ Tue, Dec 10th 2024 ] - Yahoo Finance
Shopify (SHOP) is a Great Momentum Stock: Should You Buy?
[ Tue, Dec 10th 2024 ] - The Motley Fool
3 Cruise Line Stocks to Buy Hand Over Fist in December
[ Tue, Dec 10th 2024 ] - The Motley Fool UK
Just released: December's higher-risk, high-reward stock recommendation [PREMIUM PICKS]
[ Tue, Dec 10th 2024 ] - The Motley Fool Canada
Earn $6,000 Tax-Free Annually With This TFSA Strategy
[ Tue, Dec 10th 2024 ] - The Daily Telegraph
This overlooked gem offers a fat yield while waiting for long-term growth
Mon, December 9, 2024
[ Mon, Dec 09th 2024 ] - Forbes
5 Best Undervalued Stocks To Buy In January 2025
[ Mon, Dec 09th 2024 ] - MSN
Why are Nvidia and Uber backing this $500 million artificial intelligence (AI) stock?
[ Mon, Dec 09th 2024 ] - MSN
Bernstein gives 2025 outlook on China internet stocks, upgrades JD.com
[ Mon, Dec 09th 2024 ] - MSN
Is NextEra Energy (NEE) the Best Wind Power and Solar Stock to Invest in Now?
[ Mon, Dec 09th 2024 ] - The Motley Fool
Despite Chewy's Q3 Earnings Miss, Here's Why I'd Still Buy It Before the End of 2024
[ Mon, Dec 09th 2024 ] - U.S. News & World Report
7 Best Monthly Dividend Stocks to Buy Now
[ Mon, Dec 09th 2024 ] - MSN
As the Pro Medicus share price drops 8%, should I buy more?
[ Mon, Dec 09th 2024 ] - Fidelity International
Top 10: what investment trusts did investors buy in November?
[ Mon, Dec 09th 2024 ] - The Globe and Mail
Is Super Micro Computer Set for a Comeback in 2025?
[ Mon, Dec 09th 2024 ] - Yahoo Finance
Why Epsilon Energy (EPSN) Is Among the Best Dividend Paying Debt Free Stocks to Invest in
[ Mon, Dec 09th 2024 ] - Business Insider
There are 3 reasons stocks are headed for a bear .. ket in the first half of 2025, research firm says
[ Mon, Dec 09th 2024 ] - MarketWatch
Stock Market Today: Dow ends 240 points lower as investors await this week's key inflation data
[ Mon, Dec 09th 2024 ] - The Motley Fool
3 Top Stocks to Buy This Holiday Season
[ Mon, Dec 09th 2024 ] - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock


Published on 2024-12-09 20:01:08 - Yahoo Finance
  Print publication without navigation

  • Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The article from Yahoo Finance discusses why Halozyme Therapeutics (HALO) stock has experienced a significant increase in value. It highlights that the company's stock surged after announcing a new royalty deal with the pharmaceutical company, Argenx. This deal involves the use of Halozyme's proprietary ENHANZE® drug delivery technology, which enhances the subcutaneous administration of biologics, potentially speeding up the delivery and improving patient convenience. The agreement not only validates Halozyme's technology but also promises to bring in substantial future revenue through royalties, boosting investor confidence. Additionally, the article mentions that Halozyme has been expanding its partnerships, which further supports its growth narrative. The positive market reaction is also attributed to the broader market's optimism about biologics and innovative drug delivery systems.

Read the Full YAHOO!Finance Article at:
[ https://finance.yahoo.com/news/heres-why-halozyme-therapeutics-halo-144510596.html ]
Contributing Sources